8-K filed October 17, 2025, 7:59 PM ET ticker GNPX CIK 0001595248

other material confidence medium sentiment negative materiality 0.85

Genprex granted Nasdaq exception through Oct 31, 2025; 1-for-50 reverse stock split effective Oct 21

Genprex, Inc.

Nasdaq Panel exception to demonstrate compliance with $1.00 bid price and $2.5M stockholders' equity until Oct 31, 2025; Panel may extend to Feb 9, 2026.
1-for-50 reverse stock split filed Oct 16, effective Oct 21, 2025; CUSIP changes to 372446-302; symbol remains GNPX.
Acclaim-1 (REQORSA + Tagrisso) Phase 2a enrollment ongoing; interim analysis of first 19 patients expected H2 2026.
Acclaim-3 (REQORSA + Tecentriq) Phase 2 expansion enrolling; futility analysis after 25th patient expected H2 2026.
Diabetes gene therapy GPX-002 in preclinical studies; plans to request FDA meeting for IND-enabling studies by end of 2025.

item 3.01 item 3.03 item 5.03 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-25-031210
form_type: 8-K
ticker: GNPX
cik: 0001595248
company_name: Genprex, Inc.
filed_at: 2025-10-17T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.865775+00:00
generated_at: 2026-05-17T03:23:42.324035+00:00
sec_items: ["3.01", "3.03", "5.03", "7.01", "8.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: medium
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-25-031210
json_url: https://secwatch.observer/filing/0001437749-25-031210.json
markdown_url: https://secwatch.observer/filing/0001437749-25-031210.md
text_url: https://secwatch.observer/filing/0001437749-25-031210.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/0001437749-25-031210-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/gnpx20251001_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

1d3b9ca4b8087f35be9b75eb76b6584255110772

Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5550(b)(1)).

August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.

SEC 8-K Item 3.01 confidence 0.82 SEC evidence

50cc24aac74dfda4772112233a837047c46d3599

Genprex, Inc. received a nasdaq deficiency notice notice regarding stockholders equity.

August 19, 2025, the Company received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless

SEC 8-K Item 3.01 confidence 0.95 SEC evidence

fa8706b5896184713653204b1ca8e47e54dfaac8

Genprex, Inc. received a nasdaq hearing update notice regarding minimum bid price.

received a notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, the Company was not in compliance with the Minimum Stockholders’ Equity Requirement and as previously disclosed, on August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested

SEC 8-K Item 3.01 confidence 0.95 SEC evidence

5724e42a3a5eb0b90ef3af4f69aba87840ac5116

Genprex, Inc.: Certificate of Amendment to effect a one-for-fifty reverse stock split (effective 2025-10-21).

On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

AGAE

AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K

Allied Gaming & Entertainment Inc. May 21, 2026, 9:40 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.

Comparable filing

May 19, 2026, All In FutureTech Alliance, Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of

Filing page SEC filing

PMI

Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices

Picard Medical, Inc. May 21, 2026, 4:15 PM ET other_material Items 2.02, 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.

Comparable filing

reviously disclosed, on May 8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together with the May 15 Notice, the “ Notices ”). In connection with the

Filing page SEC filing

XXI

Tether International acquires SoftBank's stake in Twenty One Capital; board members resign

Twenty One Capital, Inc. May 20, 2026, 8:49 AM ET other_material Items 1.02, 3.01, 5.02, 8.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 8.01, 9.01 same event type: other_material similar materiality

This filing

August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.

Comparable filing

o independent directors, the minimum number required during the transition period for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual

Filing page SEC filing

BKYI

BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13

BIO KEY INTERNATIONAL INC May 12, 2026, 4:46 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.

Comparable filing

May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)

Filing page SEC filing

SUJA

Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026

SUJA LIFE, INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 same event type: other_material similar materiality

This filing

On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

Comparable filing

On May 7, 2026, the Company filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware

Filing page SEC filing

ADT

Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan

ADT Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On October 16, 2025, Genprex filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time on October 21, 2025, a one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).

Comparable filing

On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.

Filing page SEC filing

ADTX

Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11

Aditxt, Inc. May 29, 2026, 4:21 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

August 12, 2025, the Company received a letter from Nasdaq indicating that, because the Company has not regained compliance with the Bid Price Requirement and because of the Company’s ineligibility for a second 180 calendar day compliance period, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requested a hearing with the Panel. The Company timely requested a hearing before the Panel, which was held on September 18, 2025.

Comparable filing

May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further

Filing page SEC filing

Source: SEC EDGAR

accession 0001437749-25-031210

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.